4D 150
Alternative Names: 4D-150Latest Information Update: 17 Jan 2025
Price :
$50 *
At a glance
- Originator 4D Molecular Therapeutics
- Class Eye disorder therapies; Gene therapies; Small interfering RNA
- Mechanism of Action Gene transference; Placenta growth factor inhibitors; RNA interference; Vascular endothelial growth factor A inhibitors; Vascular endothelial growth factor B inhibitors; Vascular endothelial growth factor C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Diabetic macular oedema
- Phase I/II Wet age-related macular degeneration
- Preclinical Diabetic retinopathy
Most Recent Events
- 17 Jan 2025 4D Molecular Therapeutics plans a pivotal phase-III 4FRONT-2 trial for Wet age-related macular degeneration in USA (Intravitreous, Injection) in Q3 2025
- 10 Jan 2025 4D Molecular Therapeutics announces intention to submit the BLA to for Diabetic macular oedema
- 10 Jan 2025 4D Molecular Therapeutics announces intention to submit the BLA to for Wet age-related macular degeneration